Hostname: page-component-77f85d65b8-s5zpc Total loading time: 0 Render date: 2026-03-26T13:18:25.343Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-acting injectable antipsychotics: what, when, and how

Published online by Cambridge University Press:  15 March 2021

Leslie Citrome Open the ORCID record for Leslie Citrome [Opens in a new window]
Leslie Citrome*
Affiliation:
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
*
*Author for correspondence: Leslie Citrome, MD, MPH Email: citrome@cnsconsultant.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Current guidelines for the treatment of patients with schizophrenia advocate that patients receive treatment with a long-acting injectable (LAI) antipsychotic medication if they prefer such treatment or if they have a history of poor or uncertain adherence. Available LAI formulations in the United States include first-generation antipsychotics (fluphenazine decanoate and haloperidol decanoate), risperidone/paliperidone containing products (risperidone microspheres, paliperidone palmitate, and risperidone subcutaneous), aripiprazole containing products (aripiprazole monohydrate and aripiprazole lauroxil), and olanzapine pamoate. LAI antipsychotics can address the guesswork about adherence status and patients may prefer them if they are offered this as a choice, including individuals early in their disease course. Additional approved indications in the United States for LAI antipsychotics include bipolar I disorder maintenance treatment for risperidone microspheres and aripiprazole monohydrate, and schizoaffective disorder for paliperidone palmitate once monthly. Differences and similarities among the different products are discussed, including guidance regarding optimal treatment selection. Tips are provided to enhance effective patient communication to maximize the likelihood of acceptance of this treatment modality.

Keywords

Depotlong-acting injectable antipsychoticschizophreniaschizoaffective disorderbipolar disorder

Information

Type
CME Review Article
Information
CNS Spectrums , Volume 26 , Issue 2 , April 2021 , pp. 118 - 129
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

This activity is supported by unrestricted educational grants from Indivior and Alkermes.

References

Volavka, J, Citrome, L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917–1928.10.1517/14656560903061309CrossRefGoogle ScholarPubMed
Valenstein, M, Ganoczy, D, McCarthy, JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542–1550.10.4088/JCP.v67n1008CrossRefGoogle ScholarPubMed
Caroli, F, Raymondet, P, Izard, I, et al. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165–171.10.2147/PPA.S15337CrossRefGoogle ScholarPubMed
Keepers, GA, Fochtmann, LJ, Anzia, JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872.10.1176/appi.ajp.2020.177901CrossRefGoogle ScholarPubMed
Lacro, JP, Dunn, LB, Dolder, CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909.10.4088/JCP.v63n1007CrossRefGoogle ScholarPubMed
Joshi, K, Lin, J, Lingohr-Smith, M, et al. Treatment patterns and antipsychotic medication adherence among commercially insured patients with schizoaffective disorder in the United States. J Clin Psychopharmacol. 2016;36(5):429–435.10.1097/JCP.0000000000000549CrossRefGoogle ScholarPubMed
Jawad, I, Watson, S, Haddad, PM, et al. Medication nonadherence in bipolar disorder: a narrative review. Ther Adv Psychopharmacol. 2018;8(12):349–363.10.1177/2045125318804364CrossRefGoogle ScholarPubMed
Dolder, CR, Lacro, JP, Jeste, DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med. 2003;65(1):156–162.10.1097/01.PSY.0000040951.22044.59CrossRefGoogle ScholarPubMed
Shafrin, J, Silverstein, AR, MacEwan, JP, et al. Using information on patient adherence to antipsychotic medication to understand their adherence to other medications. P T. 2019;44(6):350–357.Google ScholarPubMed
Law, MR, Soumerai, SB, Ross-Degnan, D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53.10.4088/JCP.v69n0107CrossRefGoogle Scholar
Weiden, PJ, Kozma, C, Grogg, A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–891.10.1176/appi.ps.55.8.886CrossRefGoogle ScholarPubMed
Morken, G, Widen, JH, Grawe, RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32.10.1186/1471-244X-8-32CrossRefGoogle ScholarPubMed
Lindenmayer, JP, Liu-Seifert, H, Kulkarni, PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990–996.10.4088/JCP.08m04221CrossRefGoogle ScholarPubMed
Alia-Klein, N, O’Rourke, TM, Goldstein, RZ, et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav. 2007;33(1):86–96.10.1002/ab.20170CrossRefGoogle Scholar
Herings, RM, Erkens, JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423–424.10.1002/pds.837CrossRefGoogle ScholarPubMed
Ascher-Svanum, H, Faries, DE, Zhu, B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–460.10.4088/JCP.v67n0317CrossRefGoogle ScholarPubMed
Hong, J, Reed, C, Novick, D, et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res. 2011;190(1):110–114.10.1016/j.psychres.2011.04.016CrossRefGoogle ScholarPubMed
Haddad, PM, Brain, C, Scott, J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.10.2147/PROM.S42735CrossRefGoogle ScholarPubMed
Citrome, L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13(7):767–783.10.1586/14737175.2013.811984CrossRefGoogle ScholarPubMed
Citrome, L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Rev Neurother. 2017;17(10):1029–1043.10.1080/14737175.2017.1371014CrossRefGoogle ScholarPubMed
Citrome, L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERIS) for the treatment of schizophrenia. Clin Schizophr Relat Psychoses. 2018;12(3):130–141.10.3371/CSRP.CI.101118CrossRefGoogle ScholarPubMed
APP Pharmaceuticals. Fluphenazine decanoate injection, USP. Prescribing Information, Revised September 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/071413s019lbl.pdf. Accessed December 24, 2020.Google Scholar
Janssen. HALDOL Decanoate 50 (haloperidol), HALDOL Decanoate 100 (haloperidol), For IM Injection Only. Prescribing Information, Revised November 2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/HALDOL+Decanoate-pi.pdf. Accessed December 24, 2020.Google Scholar
Taylor, D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52:S13–S19.10.1192/bjp.195.52.s13CrossRefGoogle ScholarPubMed
Citrome, L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199–204.10.1016/j.jns.2017.11.019CrossRefGoogle Scholar
Vinogradov, S, Fisher, M, Warm, H, et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055–1962.10.1176/appi.ajp.2009.09010017CrossRefGoogle Scholar
Ehret, MJ, Fuller, MA. Long-acting injectable risperidone. Ann Pharmacother. 2004;38(12):2122–2127. Erratum in: Ann Pharmacother. 2005;39(1):201.10.1345/aph.1E085CrossRefGoogle ScholarPubMed
Harrison, TS, Goa, KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18(2):113–132.10.2165/00023210-200418020-00005CrossRefGoogle Scholar
Janssen. RISPERDAL CONSTA (risperidone) LONG-ACTING INJECTION. Prescribing Information, Revised July 2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RISPERDAL+CONSTA-pi.pdf. Accessed December 24, 2020.Google Scholar
Eerdekens, M, Van Hove, I, Remmerie, B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91–100.10.1016/j.schres.2003.11.001CrossRefGoogle Scholar
Correll, CU, Litman, RE, Filts, Y, et al. Efficacy and safety of once-monthly Risperidone ISM in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37.10.1038/s41537-020-00127-yCrossRefGoogle ScholarPubMed
Clark, I, Taylor, D. Newer formulations of risperidone: role in the management of psychotic disorders. CNS Drugs. 2020;34(8):841–852.10.1007/s40263-020-00735-3CrossRefGoogle ScholarPubMed
Janssen. INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Prescribing Information, Revised January 2019. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf. Accessed December 24, 2020.Google Scholar
Citrome, L. Paliperidone palmitate—review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64(2):216–239.10.1111/j.1742-1241.2009.02240.xCrossRefGoogle ScholarPubMed
Greenberg, WM, Citrome, L. Paliperidone palmitate for schizoaffective disorder: a review of the clinical evidence. Neurol Ther. 2015;4(2):81–91.10.1007/s40120-015-0030-4CrossRefGoogle ScholarPubMed
Russu, A, Kern Sliwa, J, Ravenstijn, P, et al. Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: practical guidance based on pharmacokinetic simulations. Int J Clin Pract. 2018;72(6):e13089.10.1111/ijcp.13089CrossRefGoogle ScholarPubMed
Janssen. INVEGA TRINZA (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Prescribing Information, Revised January 2019. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf. Accessed December 24, 2020.Google Scholar
Ravenstijn, P, Remmerie, B, Savitz, A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–339.10.1002/jcph.597CrossRefGoogle ScholarPubMed
Indivior. PERSERIS (risperidone) for extended-release injectable suspension, for subcutaneous use. Prescribing Information, Revised December 2019. https://www.perserishcp.com/prescribing-information.pdf. Accessed December 24, 2020.Google Scholar
Citrome, L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169–186.10.1586/17512433.2016.1121809CrossRefGoogle ScholarPubMed
Ehret, MJ, Davis, E, Luttrell, SE, et al. Aripiprazole lauroxil nanocrystal dispersion technology (Aristada Initio). Clin Schizophr Relat Psychoses. 2018;12(2):92–96.10.3371/CSRP.EHDA071918CrossRefGoogle Scholar
Hard, ML, Wehr, A, von Moltke, L, et al. Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil nanocrystal dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. Ther Adv Psychopharmacol. 2019;9:2045125319859964.10.1177/2045125319859964CrossRefGoogle ScholarPubMed
Otsuka. ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, for intramuscular use. Prescribing Information, Revised June 2020. https://www.otsuka-us.com/sites/g/files/qhldwo2966/files/media/static/Abilify-M-PI.pdf. Accessed December 24, 2020.Google Scholar
Alkermes. ARISTADA (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. Prescribing Information, Revised October 2020. https://www.aristadahcp.com/downloadables/ARISTADA-PI.pdf. Accessed December 24, 2020.Google Scholar
Alkermes. ARISTADA INITIO (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. Prescribing Information, Revised October 2020. https://www.aristadahcp.com/downloadables/ARISTADA-INITIO-PI.pdf. Accessed December 24, 2020.Google Scholar
Hard, ML, Wehr, AY, Du, Y, et al. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. J Clin Psychopharmacol. 2018;38(5):435–441.10.1097/JCP.0000000000000921CrossRefGoogle Scholar
Raoufinia, A, Peters-Strickland, T, Nylander, AG, et al. Aripiprazole once-monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017;20(4):295–304.10.1093/ijnp/pyw116CrossRefGoogle ScholarPubMed
Lilly. ZYPREXA RELPREVV (olanzapine) for extended release injectable suspension. Prescribing Information, Revised July 2020. http://pi.lilly.com/us/zyprexa_relprevv.pdf. Accessed December 24, 2020.Google Scholar
Citrome, L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140–150.10.1111/j.1742-1241.2008.01900.xCrossRefGoogle Scholar
Citrome, L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence. 2009;3:345–355.10.2147/PPA.S5734CrossRefGoogle ScholarPubMed
Detke, HC, McDonnell, DP, Brunner, E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010;10:43.10.1186/1471-244X-10-43CrossRefGoogle ScholarPubMed
Luedecke, D, Schöttle, D, Karow, A, et al. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015;29(1):41–46.10.1007/s40263-014-0216-9CrossRefGoogle ScholarPubMed
Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. Erratum in: Lancet. 2013;382(9896):940.10.1016/S0140-6736(13)60733-3CrossRefGoogle ScholarPubMed
Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. Erratum in: Lancet. 2019;394(10202):918.10.1016/S0140-6736(19)31135-3CrossRefGoogle ScholarPubMed
Pandina, GJ, Lindenmayer, JP, Lull, J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235–244. Erratum in: J Clin Psychopharmacol. 2010;30(4):364.10.1097/JCP.0b013e3181dd3103CrossRefGoogle ScholarPubMed
Gopal, S, Hough, DW, Xu, H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247–256.10.1097/YIC.0b013e32833948faCrossRefGoogle ScholarPubMed
Nasrallah, HA, Gopal, S, Gassmann-Mayer, C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–2082.10.1038/npp.2010.79CrossRefGoogle Scholar
Kramer, M, Litman, R, Hough, D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635–647.10.1017/S1461145709990988CrossRefGoogle ScholarPubMed
Lauriello, J, Lambert, T, Andersen, S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790–799. Erratum in: J Clin Psychiatry. 2011;72(8):1157.10.4088/JCP.v69n0512CrossRefGoogle ScholarPubMed
Kane, JM, Peters-Strickland, T, Baker, RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254–1260.10.4088/JCP.14m09168CrossRefGoogle ScholarPubMed
Meltzer, HY, Risinger, R, Nasrallah, HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085–1090.10.4088/JCP.14m09741CrossRefGoogle ScholarPubMed
Nasser, AF, Henderson, DC, Fava, M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–140.10.1097/JCP.0000000000000479CrossRefGoogle ScholarPubMed
Citrome, L, Du, Y, Risinger, R, Stankovic, S, et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Int Clin Psychopharmacol. 2016;31(2):69–75.10.1097/YIC.0000000000000106CrossRefGoogle ScholarPubMed
Citrome, L, Volavka, J. Specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine. Harv Rev Psychiatry. 2021;29(1):20–34.10.1097/HRP.0000000000000275CrossRefGoogle ScholarPubMed
Citrome, L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138–147.10.1097/JCP.0000000000000665CrossRefGoogle ScholarPubMed
Janssen. RISPERDAL (risperidone) tablets, for oral use; RISPERDAL (risperidone) oral solution; RISPERDAL M-TAB (risperidone) orally disintegrating tablets. Prescribing Information, Revised January 2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RISPERDAL-pi.pdf. Accessed December 25, 2020.Google Scholar
Janssen. INVEGA (paliperidone) Extended-Release Tablets. Prescribing Information, Revised January 2019. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA-pi.pdf. Accessed December 25, 2020.Google Scholar
Otsuka. ABILIFY (aripiprazole) Tablets; ABILIFY DISCMELT (aripiprazole) Orally Disintegrating Tablets; ABILIFY (aripiprazole) Oral Solution; ABILIFY (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY. Prescribing Information, Revised June 2020. https://www.otsuka-us.com/sites/g/files/qhldwo2966/files/media/static/Abilify-PI.pdf. Accessed December 25, 2020.Google Scholar
Lilly. ZYPREXA (olanzapine) Tablet for Oral use; ZYPREXA ZYDIS (olanzapine) Tablet, Orally Disintegrating for Oral use; ZYPREXA IntraMuscular (olanzapine) Injection, Powder, For Solution for Intramuscular use. Prescribing Information, Revised April 2020. https://pi.lilly.com/us/zyprexa-pi.pdf. Accessed December 25, 2020.Google Scholar
Kirson, NY, Weiden, PJ, Yermakov, S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568–575.10.4088/JCP.12r08167CrossRefGoogle ScholarPubMed
Emsley, R, Fleischhacker, WW, Galderisi, S, et al. Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. BMJ. 2016;354:i4728.Google Scholar
Hough, D, Gopal, S, Vijapurkar, U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2–3):107–117.10.1016/j.schres.2009.10.026CrossRefGoogle ScholarPubMed
Berwaerts, J, Liu, Y, Gopal, S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–839.10.1001/jamapsychiatry.2015.0241CrossRefGoogle ScholarPubMed
Kane, JM, Detke, HC, Naber, D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181–189.10.1176/appi.ajp.2009.07081221CrossRefGoogle ScholarPubMed
Kane, JM, Sanchez, R, Perry, PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617–624.10.4088/JCP.11m07530CrossRefGoogle ScholarPubMed
Macfadden, W, Alphs, L, Haskins, JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827–839.10.1111/j.1399-5618.2009.00761.xCrossRefGoogle ScholarPubMed
Quiroz, JA, Yatham, LN, Palumbo, JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156–162.10.1016/j.biopsych.2010.01.015CrossRefGoogle ScholarPubMed
Calabrese, JR, Sanchez, R, Jin, N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017;78(3):324–331.10.4088/JCP.16m11201CrossRefGoogle ScholarPubMed
Fu, DJ, Turkoz, I, Simonson, RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):253–262.10.4088/JCP.14m09416CrossRefGoogle Scholar
US Food and Drug Administration. Drug Approval Package, Zyprexa Relprevv (olanzapine) for Extended Release Injectable Suspension 210 mg, 300 mg, and 405 mg, Company: Eli Lilly and Company, Application No.: 022173, Approval Date: 12/11/2009. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022173_zyprexa_relprevv_toc.cfm. Accessed December 25, 2020.Google Scholar
Ceraso, A, Lin, JJ, Schneider-Thoma, J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;8:CD008016Google Scholar
Stahl, SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19(1):3–5.10.1017/S1092852913001016CrossRefGoogle ScholarPubMed
Gardner, KN, Nasrallah, HA. Managing first-episode psychosis: rationale and evidence for nonstandard first-line treatments for schizophrenia. Current Psychiatry. 2015;14(7):33, 38–45, e3.Google Scholar
Lieberman, JA, Alvir, JM, Koreen, A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(3 Suppl):13S–21S.10.1016/0893-133X(95)00200-WCrossRefGoogle Scholar
Birchwood, M, Todd, P, Jackson, C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53–59.10.1192/S0007125000297663CrossRefGoogle ScholarPubMed
Tiihonen, J, Haukka, J, Taylor, M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. Erratum in: Am J Psychiatry. 2012;169(2):223.10.1176/appi.ajp.2011.10081224CrossRefGoogle Scholar
Robinson, D, Woerner, MG, Alvir, JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.10.1001/archpsyc.56.3.241CrossRefGoogle ScholarPubMed
Robinson, DG, Woerner, MG, Alvir, JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2–3):209–219.10.1016/S0920-9964(01)00312-7CrossRefGoogle ScholarPubMed
Subotnik, KL, Casaus, LR, Ventura, J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829.10.1001/jamapsychiatry.2015.0270CrossRefGoogle ScholarPubMed
Schreiner, A, Aadamsoo, K, Altamura, AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399.10.1016/j.schres.2015.08.015CrossRefGoogle ScholarPubMed
Kane, JM, Schooler, NR, Marcy, P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1–8. Erratum in: doi:10.1001/jamapsychiatry.2020.3302.CrossRefGoogle ScholarPubMed
Jaeger, M, Rossler, W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175(1–2):58–62.10.1016/j.psychres.2008.11.003CrossRefGoogle ScholarPubMed
Haque, SF, D’Souza, A. Motivational interviewing: The RULES, PACE, and OARS. Current Psychiatry. 2019;18(1):27–28.Google Scholar
Lewis-Fernández, R, Coombs, AA, Balán, IC, et al. Motivational interviewing: overcoming disparities in pharmacotherapy engagement. J Clin Psychiatry. 2018;79(3):18ac12150.10.4088/JCP.18ac12150CrossRefGoogle ScholarPubMed
Ren, Y, Yang, H, Browning, C, et al. Therapeutic effects of motivational interviewing on blood pressure control: a meta-analysis of randomized controlled trials. Int J Cardiol. 2014;172(2):509–511.10.1016/j.ijcard.2014.01.051CrossRefGoogle ScholarPubMed
Naderi, SH, Bestwick, JP, Wald, DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7.e.1.10.1016/j.amjmed.2011.12.013CrossRefGoogle ScholarPubMed
Briesacher, BA, Andrade, SE, Fouayzi, H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437–443.10.1592/phco.28.4.437CrossRefGoogle ScholarPubMed
Weiden, PJ, Roma, RS, Velligan, DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684–690.10.4088/JCP.13m08946CrossRefGoogle ScholarPubMed
Remington, GJ, Adams, ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry. 1995;40(3 Suppl 1):S5–S11.Google ScholarPubMed
Demers, MF, Bilodeau, I, Laberge, L, et al. SU112. The dark side of haloperidol decanoate shortage in Canada. Schizophr Bull. 2017;43(Suppl 1):S201–S202.10.1093/schbul/sbx024.108CrossRefGoogle Scholar